Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 study.

Blood vessels, thrombosis & hemostasis·2026
Same author

Prognostic utility of procalcitonin and lactate clearance for in-hospital mortality in sepsis.

Frontiers in medicine·2025
Same author

Are Thrombolytics Useful in Out-of-Hospital Cardiac Arrest?

Cureus·2025
Same author

BCL2-Rearrangment-Negative CD23+ Follicle Center Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case of Biclonal Composite Lymphoma.

Cureus·2025
Same author

Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials.

Blood vessels, thrombosis & hemostasis·2025
Same author

Increasing Olanzapine Prescribing for Patients Undergoing Highly Emetogenic Chemotherapy.

JAMA network open·2025
Same journal

SMA's 6th Annual Physicians-in-Training Leadership Conference Abstract Presentations.

Southern medical journal·2026
Same journal

Potential Impact of Lower Federal Loan Availability on Medical Education in Appalachia.

Southern medical journal·2026
Same journal

Experiential Mentorship Skills Training: The Effect on Real-Life Mentoring.

Southern medical journal·2026
Same journal

Social Pressure: How Early Social Context Shapes Career Interest in Medicine.

Southern medical journal·2026
Same journal

Comparing Speed and Accuracy of Artificial Intelligence Large Language Models on the Orthopedic In-Training Examination.

Southern medical journal·2026
Same journal

Don't Wait to Talk about Weight: A 2-Hour Interactive Curriculum Improves Medical Student Skills with Weight Management.

Southern medical journal·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Unexplained macrocytosis.

Mohamad Younes1, Gilbert Abou Dagher, Jose V Dulanto

  • 1Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202, USA. myounis83@hotmail.com

Southern Medical Journal
|February 6, 2013
PubMed
Summary
This summary is machine-generated.

Unexplained macrocytosis in adults warrants close monitoring. A significant percentage may develop bone marrow disorders, necessitating regular blood counts and timely bone marrow biopsies if cytopenias arise.

More Related Videos

Isolation and Culture of Bone Marrow-Derived Macrophages from Mice
07:12

Isolation and Culture of Bone Marrow-Derived Macrophages from Mice

Published on: June 23, 2023

Related Experiment Videos

Last Updated: May 14, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Isolation and Culture of Bone Marrow-Derived Macrophages from Mice
07:12

Isolation and Culture of Bone Marrow-Derived Macrophages from Mice

Published on: June 23, 2023

Area of Science:

  • Hematology
  • Internal Medicine

Background:

  • Macrocytosis is a common finding in blood counts.
  • Unexplained macrocytosis occurs in about 10% of patients after initial lab evaluation.
  • Limited data exists on managing unexplained macrocytosis.

Purpose of the Study:

  • To investigate the outcomes of patients with unexplained macrocytosis.
  • To delineate a management approach for unexplained macrocytosis.

Main Methods:

  • Retrospective review of 9779 patients with macrocytosis (1995-2005).
  • Exclusion of patients with known causes of macrocytosis (liver disease, alcohol, hypothyroidism, vitamin deficiencies, hemolysis, certain medications).
  • Analysis of outcomes in 43 patients with unexplained macrocytosis.

Main Results:

  • 11.6% developed primary bone marrow disorders (lymphoma, myelodysplastic syndrome, plasma cell disorder).
  • 16.3% developed worsening cytopenias.
  • Median follow-up was 4 years; median time to cytopenia was 18 months.

Conclusions:

  • Patients with unexplained macrocytosis require ongoing surveillance.
  • Recommend blood cell counts every 6 months.
  • Bone marrow biopsy is indicated for patients with cytopenias to improve diagnostic yield.